- A15015A (See other available formats)
- Other Names
- Macrophage inflammatory protein 1 (MIP1ž„), Macrophage inflammatory protein 5 (MIP5), Leukotactin 1 (LKN1), Hemofiltrate chemokine 2 (HCC-2), New CC chemokine 3 (NCC3)
- Mouse IgG2a, κ
- Ave. Rating
- Submit a Review
- Product Citations
|Cat #||Size||Price||Quantity Avail.||Save|
CCL15 was discovered by analyzing the upstream region of the CCL14 gene. CCL15 is arranged in tandem with CCL14 on human chromosome 17. CCL15, CCL6, CCL9, and CCL23 have an extended N-terminal domain upstream of the first two conserved chemokine cysteines. This domain is encoded by a different exon and includes 16 to 20 residues. CCL15 (1-92) is processed by cathepsin G to produce highly active forms of CCL15 [(24-92), (27-92) and (29-92)], and elastase processes CCL15 (1-92) predominantly to CCL15 (22-92). Also, CCL15 is cleaved by MT6-MMP/MMP25 to produce CCL15 with very high activity. MMP25 is localized primarily in neutrophil gelatinase granules, and it is released by neutrophil activation and degranulation in inflammatory reactions. High levels of CCL15 were detected in human renal cell carcinoma bone metastasis, and in vitro studies showed that CCL15 stimulates chemotaxis of osteoclast progenitors and enhances their differentiation in response to RANKL. CCL15 is abundant in bronchoalveolar lavage of patients with pulmonary sarcoidosis. Also, it is elevated in the serum of patients with severe asthma, and it is reduced by omalizumab, a humanized anti-IgE antibody that has been use in the treatment of asthma. It has been suggested that airway smooth muscle cells and basophils produce CCL15, and it might have an important role in asthma severity and persistence. In addition, high levels of CCL15 have been detected in the serum of patients with hepatocellular carcinoma, and human hepatic carcinoma cells express CCR1 and CCL15.Product Details
- Antibody Type
- Host Species
- Recombinant human CCL15.
- 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative. Endotoxin level is <0.01 EU/µg of the protein (<0.001 ng/µg of the protein) as determined by the LAL test.
- The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
- The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. Please contact technical support for concentration and total µg amount, or use our Lookup tool if you have a lot number.
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Block - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by blocking. The ND50 is 0.05 - 0.25 µg/mL. It is recommended that the reagent be titrated for optimal performance for each application.
AB_2632767 (BioLegend Cat. No. 692703)
AB_2632768 (BioLegend Cat. No. 692704)
- CCL15 is produced by smooth muscle cells, basophils, and hepatic carcinoma cells.
- CCL15 induces migration of monocytes, eosinophils, and lymphocytes. CCL15 is activated by cathepsin G, elastase, and MMPs. TNFÎ± and IFNÎ³ synergistically induce CCL15 in human airway smooth muscle cells in culture.
- Monocytes, eosinophils, airway smooth muscle cells, hepatic carcinoma cells, human osteogenic sarcoma cells, and osteoclast progenitors.
- CCR1, CCR3.
- Cell Type
- Biology Area
- Cell Biology, Immunology
- Molecular Family
- Antigen References
1. Pardigol A, et al. 1998. Proc. Natl. Acad. Sci. USA 95:6308.
2. Richter R, et al. 2005. J. Immunol. 175:1599.
3. Berahovich RD, et al. 2005. J. Immunol. 174:7341.
4. Shimizu Y, et al. 2011. J. Biol. Regul. Homeost. Agents 25:177.
5. Starr AE, et al. 2012. J. Biol. Chem. 287:13382.
6. Weber KL, et al. 2012. PLoS One 7:e40799.
7. Li Y, et al. 2013. Br. J. Cancer 108:99.
- Gene ID
- 6359 View all products for this Gene ID
- View information about CCL15 on UniProt.org
- Does BioLegend test each Ultra-LEAF™ antibody by functional assay?
No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.
- Do you guarantee that your antibodies are totally pathogen free?
BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.
- Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?
No, BioLegend does not test for pathogens in-house unless otherwise indicated. However, we can recommend an outside vendor to perform this testing as needed.
- Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?
We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.
Compare Data Across All Formats
This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.